Consensus stock forecasts and twelve-month price targets provided by Wall Street healthcare analysts covering Karyopharm Therapeutics point toward an average target range of approximately seven to seven-and-a-half United States dollars per share. Individual analyst projections span from conservative low estimates of three dollars up to optimistic high estimates reaching eleven dollars. These forecasts reflect anticipated clinical pipeline advancements and commercial milestones, though targets remain sensitive to trial readouts and regulatory updates.